{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:48:32Z","timestamp":1791492512891,"version":"4.3.4"},"reference-count":39,"publisher":"American Association for the Advancement of Science (AAAS)","issue":"658","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Sci. Transl. Med."],"published-print":{"date-parts":[[2022,8,17]]},"abstract":"<jats:p>Transmission-blocking strategies that slow the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and protect against coronavirus disease 2019 (COVID-19) are needed. We have developed an orally delivered adenovirus type 5\u2013vectored SARS-CoV-2 vaccine candidate that expresses the spike protein. Here, we demonstrated that hamsters vaccinated by the oral or intranasal route had robust and cross-reactive antibody responses. We then induced a postvaccination infection by inoculating vaccinated hamsters with SARS-CoV-2. Orally or intranasally vaccinated hamsters had decreased viral RNA and infectious virus in the nose and lungs and experienced less lung pathology compared to mock-vaccinated hamsters after SARS-CoV-2 challenge. Na\u00efve hamsters exposed in a unidirectional air flow chamber to mucosally vaccinated, SARS-CoV-2\u2013infected hamsters also had lower nasal swab viral RNA and exhibited fewer clinical symptoms than control animals, suggesting that the mucosal route reduced viral transmission. The same platform encoding the SARS-CoV-2 spike and nucleocapsid proteins elicited mucosal cross-reactive SARS-CoV-2\u2013specific IgA responses in a phase 1 clinical trial (NCT04563702). Our data demonstrate that mucosal immunization is a viable strategy to decrease SARS-CoV-2 disease and airborne transmission.<\/jats:p>","DOI":"10.1126\/scitranslmed.abn6868","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T13:58:12Z","timestamp":1651759092000},"source":"Crossref","is-referenced-by-count":116,"title":["Adenovirus type 5 SARS-CoV-2 vaccines delivered orally or intranasally reduced disease severity and transmission in a hamster model"],"prefix":"10.1126","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0467-7874","authenticated-orcid":true,"given":"Stephanie N.","family":"Langel","sequence":"first","affiliation":[{"name":"Department of Surgery, Duke University Medical School, Duke University, Durham, NC 27710, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4302-7903","authenticated-orcid":true,"given":"Susan","family":"Johnson","sequence":"additional","affiliation":[{"name":"Vaxart, South San Francisco, CA 94080, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4075-9348","authenticated-orcid":true,"given":"Clarissa I.","family":"Martinez","sequence":"additional","affiliation":[{"name":"Vaxart, South San Francisco, CA 94080, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0933-6737","authenticated-orcid":true,"given":"Sarah N.","family":"Tedjakusuma","sequence":"additional","affiliation":[{"name":"Vaxart, South San Francisco, CA 94080, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Peinovich","sequence":"additional","affiliation":[{"name":"Vaxart, South San Francisco, CA 94080, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0587-2751","authenticated-orcid":true,"given":"Emery G.","family":"Dora","sequence":"additional","affiliation":[{"name":"Vaxart, South San Francisco, CA 94080, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7567-3002","authenticated-orcid":true,"given":"Philip J.","family":"Kuehl","sequence":"additional","affiliation":[{"name":"Lovelace Biomedical Research Institute, Albuquerque, NM 87108, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9342-9874","authenticated-orcid":true,"given":"Hammad","family":"Irshad","sequence":"additional","affiliation":[{"name":"Lovelace Biomedical Research Institute, Albuquerque, NM 87108, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0521-0683","authenticated-orcid":true,"given":"Edward G.","family":"Barrett","sequence":"additional","affiliation":[{"name":"Lovelace Biomedical Research Institute, Albuquerque, NM 87108, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8977-5704","authenticated-orcid":true,"given":"Adam D.","family":"Werts","sequence":"additional","affiliation":[{"name":"Lovelace Biomedical Research Institute, Albuquerque, NM 87108, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6233-225X","authenticated-orcid":true,"given":"Sean N.","family":"Tucker","sequence":"additional","affiliation":[{"name":"Vaxart, South San Francisco, CA 94080, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32661-1"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2108076"},{"key":"e_1_3_3_6_2","doi-asserted-by":"crossref","unstructured":"P. Y. Chia S. W. X. Ong C. J. Chiew L. W. Ang J.-M. Chavatte T.-M. Mak L. Cui S. Kalimuddin W. N. Chia C. W. Tan L. Y. A. Chai S. Y. Tan S. Zheng R. T. P. Lin L. Wang Y.-S. Leo V. J. Lee D. C. Lye B. E. Young Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: A multi-center cohort study. medRxiv 2021.07.28.21261295 (2021).","DOI":"10.1101\/2021.07.28.21261295"},{"key":"e_1_3_3_7_2","doi-asserted-by":"crossref","unstructured":"F. P. Lyngse K. M\u00f8lbak M. Denwood L. E. Christiansen C. H. M\u00f8ller M. Rasmussen A. S. Cohen M. Stegger J. Fonager R. Sieber K. Ellegaard C. Nielsen C. T. Kirkeby Effect of vaccination on household transmission of SARS-CoV-2 delta VOC. medRxiv 2022.01.06.22268841 (2022).","DOI":"10.1101\/2022.01.06.22268841"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04388-0"},{"key":"e_1_3_3_9_2","unstructured":"R.-G. L. II L. Money LA Times 2022; www.latimes.com\/california\/story\/2022-01-13\/california-omicron-surge-expected-to-peak-within-weeks 2022."},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-020-00468-6"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.121077"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30584-5"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.01.023"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2021.10.009"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2007.14"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri1203"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009865"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20439-y"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009195"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2009799117"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202000886"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01316-7"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab561"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd2223"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc7424"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18058-8"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1503885112"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.20173"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0143-6"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00743-3"},{"key":"e_1_3_3_31_2","doi-asserted-by":"crossref","unstructured":"B. A. Flitter C. A. Lester S. N. Tedjakusuma E. G. Dora N. Peinovich M. Cortese C. I. Martinez C. B. Jegede E. D. Neuhaus S. N. Tucker Mucosal immunization of cynomolgus macaques with adenoviral vector vaccine elicits neutralizing nasal and serum antibody to several SARS-CoV-2 variants. bioRxiv 2022.02.21.481345 [ Preprint ]. 2022.","DOI":"10.1101\/2022.02.21.481345"},{"key":"e_1_3_3_32_2","doi-asserted-by":"crossref","unstructured":"R. G. King A. Silva-Sanchez J. N. Peel D. Botta S. Meza-Perez S. Rameeza Allie M. D. Schultz M. Liu J. E. Bradley S. Qiu G. Yang F. Zhou E. Zumaquero T. S. Simpler B. Mousseau John T. Killian Jr. B. Dean Q. Shang J. L. Tipper C. Risley K. S. Harrod R. Feng Y. Lee B. Shiberu V. Krishnan I. Peguillet J. Zhang J. Todd Green T. D. Randall B. Georges F. E. Lund S. Roberts Single-dose intranasal administration of AdCOVID elicits systemic and mucosal immunity against SARS-CoV-2 in mice. bioRxiv 2020.10.10.331348 [ Preprint ]. 2020.","DOI":"10.1101\/2020.10.10.331348"},{"key":"e_1_3_3_33_2","unstructured":"Altimmune \u201cUpdate On AdCOVID Phase 1 Clinical Trial \u201d https:\/\/ir.altimmune.com\/news-releases\/news-release-details\/altimmune-announces-update-adcovidtm-phase-1-clinical-trial ."},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000572"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.15.19"},{"key":"e_1_3_3_36_2","doi-asserted-by":"crossref","unstructured":"A. C. Moore E. G. Dora N. Peinovich K. P. Tucker K. Lin Mario Cortese S. N. Tucker Pre-clinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection. bioRxiv 2020.09.04.283853 [ Preprint ]. 2020.","DOI":"10.1101\/2020.09.04.283853"},{"key":"e_1_3_3_37_2","unstructured":"M. A. Kohn J. Senyak Sample Size Calculations. [https:\/\/sample-size.net\/sample-size-proportions\/] UCSF CTSI. Latest version 22 June 2022. [Accessed in 2021]"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.5.2509"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0024448"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a118408"}],"container-title":["Science Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.science.org\/doi\/pdf\/10.1126\/scitranslmed.abn6868","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T12:24:48Z","timestamp":1705407888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.science.org\/doi\/10.1126\/scitranslmed.abn6868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,17]]},"references-count":39,"journal-issue":{"issue":"658","published-print":{"date-parts":[[2022,8,17]]}},"alternative-id":["10.1126\/scitranslmed.abn6868"],"URL":"https:\/\/doi.org\/10.1126\/scitranslmed.abn6868","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.10.03.462919","asserted-by":"object"}]},"ISSN":["1946-6234","1946-6242"],"issn-type":[{"value":"1946-6234","type":"print"},{"value":"1946-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,17]]},"article-number":"eabn6868"}}